Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Evgen Pharma ( (GB:TCF) ) just unveiled an announcement.
TheraCryf plc has announced the appointment of Edward Wardle as a Non-Executive Director, nominated by its largest shareholder, Tracarta Ltd. The company has also granted options over 289,820,870 Ordinary Shares to certain employees and Persons Discharging Managerial Responsibility, aligning management incentives with shareholder interests. This strategic move is part of TheraCryf’s efforts to focus on its neuropsychiatry assets and maximize shareholder value, particularly through the Ox-1 antagonist program. Additionally, Dr. Alastair Smith, the Non-Executive Chair, has opted to receive his board fees in shares to extend the company’s cash runway.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
The overall stock score reflects significant financial and technical challenges facing Evgen Pharma, including declining revenues and negative cash flow. However, recent positive corporate events and strategic initiatives provide a glimmer of hope for future improvement. The stock’s current valuation remains unattractive due to ongoing losses, contributing to a cautious outlook.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company based in Alderley Park, UK, focusing on neuropsychiatry and oncology. The company is listed on AIM with a market focus on developing innovative treatments, including the Ox-1 antagonist program for addiction.
YTD Price Performance: -56.73%
Average Trading Volume: 4,042,645
Technical Sentiment Signal: Buy
Current Market Cap: £4.79M
For an in-depth examination of TCF stock, go to TipRanks’ Stock Analysis page.